Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AMGN

AMGN - Amgen Inc Stock Price, Fair Value and News

331.29USD+0.32 (+0.10%)Market Closed

Market Summary

AMGN
USD331.29+0.32
Market Closed
0.10%

AMGN Stock Price

View Fullscreen

AMGN RSI Chart

AMGN Valuation

Market Cap

177.7B

Price/Earnings (Trailing)

47.23

Price/Sales (Trailing)

6.02

EV/EBITDA

18.89

Price/Free Cashflow

25.04

AMGN Price/Sales (Trailing)

AMGN Profitability

EBT Margin

14.71%

Return on Equity

74.93%

Return on Assets

4.05%

Free Cashflow Yield

3.99%

AMGN Fundamentals

AMGN Revenue

Revenue (TTM)

29.5B

Rev. Growth (Yr)

21.98%

Rev. Growth (Qtr)

-9.14%

AMGN Earnings

Earnings (TTM)

3.8B

Earnings Growth (Yr)

-103.98%

Earnings Growth (Qtr)

-114.73%

Breaking Down AMGN Revenue

Last 7 days

0.1%

Last 30 days

8.3%

Last 90 days

23.2%

Trailing 12 Months

42.0%

How does AMGN drawdown profile look like?

AMGN Financial Health

Current Ratio

1.42

Debt/Equity

11.96

Debt/Cashflow

0.13

AMGN Investor Care

Dividend Yield

2.57%

Dividend/Share (TTM)

8.64

Shares Dilution (1Y)

0.39%

Diluted EPS (TTM)

7.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202429.5B000
202326.2B26.6B26.8B28.2B
202226.3B26.4B26.3B26.3B
202125.2B25.5B25.8B26.0B
202024.0B24.3B25.0B25.4B
201923.8B23.6B23.4B23.4B
201822.9B23.2B23.3B23.7B
201722.9B23.1B23.0B22.8B
201622.2B22.5B22.6B23.0B
201520.6B20.8B21.5B21.7B
201419.0B19.5B19.7B20.1B
201317.5B17.7B18.1B18.7B
201215.9B16.4B16.8B17.3B
201115.2B15.3B15.4B15.6B
201014.9B15.0B15.0B15.1B
200914.7B14.6B14.6B14.6B
2008014.8B14.9B15.0B
200700014.8B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amgen Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 31, 2024
jacks tyler
acquired
-
-
719
-
May 31, 2024
holley charles m
acquired
-
-
719
-
May 31, 2024
ishrak omar
acquired
-
-
719
-
May 31, 2024
drake michael v
acquired
-
-
719
-
May 31, 2024
druker brian
acquired
-
-
719
-
May 31, 2024
austin wanda m
acquired
-
-
719
-
May 31, 2024
kullman ellen jamison
acquired
-
-
719
-
May 31, 2024
miles amy e
acquired
-
-
719
-
May 31, 2024
eckert robert
acquired
-
-
719
-
May 31, 2024
garland greg c.
acquired
-
-
719
-

1–10 of 50

Which funds bought or sold AMGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
Zhang Financial LLC
added
1.09
466,276
4,671,160
0.33%
Jul 19, 2024
Accredited Investors Inc.
added
0.19
60,675
662,282
0.04%
Jul 19, 2024
Lifestyle Asset Management, Inc.
reduced
-10.78
-4,332
217,153
0.12%
Jul 19, 2024
KAVAR CAPITAL PARTNERS GROUP, LLC
unchanged
-
29,537
328,073
0.06%
Jul 19, 2024
Summit Financial Strategies, Inc.
unchanged
-
39,382
437,430
0.05%
Jul 19, 2024
Hennion & Walsh Asset Management, Inc.
reduced
-2.56
234,380
3,544,430
0.18%
Jul 19, 2024
FIRST CITIZENS BANK & TRUST CO
added
0.07
270,829
2,986,080
0.06%
Jul 19, 2024
First Pacific Financial
unchanged
-
618
6,874
-%
Jul 19, 2024
Western Wealth Management, LLC
reduced
-30.08
-342,576
1,136,800
0.08%
Jul 19, 2024
Ironwood Financial, llc
unchanged
-
163,520
1,816,270
0.41%

1–10 of 48

Are Funds Buying or Selling AMGN?

Are funds buying AMGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMGN
No. of Funds

Unveiling Amgen Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.16%
49,036,311
SC 13G/A
Jan 30, 2024
state street corp
5.52%
29,543,705
SC 13G/A
Jan 25, 2024
blackrock inc.
8.9%
47,811,356
SC 13G/A
Feb 09, 2023
vanguard group inc
9.01%
48,065,139
SC 13G/A
Feb 07, 2023
blackrock inc.
9.1%
48,513,079
SC 13G/A
Feb 06, 2023
state street corp
5.58%
29,760,088
SC 13G/A
Feb 11, 2022
capital research global investors
3.9%
22,157,906
SC 13G/A
Feb 10, 2022
state street corp
5.37%
30,221,708
SC 13G/A
Feb 09, 2022
vanguard group inc
8.28%
46,661,009
SC 13G/A
Feb 01, 2022
blackrock inc.
8.9%
50,046,345
SC 13G/A

Recent SEC filings of Amgen Inc

View All Filings
Date Filed Form Type Document
Jun 21, 2024
11-K
Employee Benefit Details
Jun 21, 2024
11-K
Employee Benefit Details
Jun 12, 2024
S-8
Employee Benefits Plan
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
3
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading

Peers (Alternatives to Amgen Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
372.4B
85.6B
6.23% -8.11%
9.68
4.35
5.68% 202.39%
318.7B
61.4B
-1.70% 16.00%
138.18
5.19
6.11% -82.30%
177.7B
29.5B
8.27% 42.04%
47.23
6.02
12.76% -52.47%
169.7B
35.0B
9.27% -18.55%
146.05
4.84
-26.40% -92.03%
90.4B
27.4B
14.93% -9.21%
186.63
3.29
1.51% -91.32%
18.9B
16.0B
-1.18% 98.47%
-38.18
1.18
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.72% -22.30%
9.68
2.44
54.01% 364.56%
3.8B
4.6B
9.59% -20.45%
-495.71
0.84
-0.06% 94.55%
2.8B
9.0B
17.62% -20.65%
-6.13
0.31
10.01% -27.45%
1.9B
676.2M
-1.12% -37.39%
12.52
2.86
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
5.33% 7.88%
-3.91
1.85
24.65% 80.36%
21.2M
1.3M
-1.08% -55.56%
-2.86
16.12
-98.14% -104.71%
14.8M
89.6M
11.54% -18.69%
-1.04
0.19
287.27% -129.41%
9.8M
21.5M
320.59% -52.65%
-1.26
0.46
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Amgen Inc News

Latest updates
Defense World24 hours ago
TradingView17 Jul 202401:57 pm

Amgen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-9.1%7,4478,1966,9036,9866,1056,8396,6526,5946,2386,8466,7066,5265,9016,6346,4236,2066,1616,1975,7375,8715,557
Costs and Expenses-6.8%6,4566,9254,8824,3024,1844,6093,9924,4183,7384,5424,3285,6983,7724,6263,9703,8833,8064,1493,2613,1933,085
  S&GA Expenses-20.5%1,8082,2741,3531,2941,2581,5721,2871,3271,2281,4251,3051,3841,2541,7731,3461,2951,3161,5131,2231,2601,154
EBITDA Margin-22.2%0.41*0.53*0.55*0.56*0.54*0.46*0.47*0.46*0.42*0.43*-----------
Interest Expenses0.4%824821759752543415368328295335296281285318302296346301313332343
Income Taxes-47.1%45.0085.0021723560113224921419923227194.00211262185227195280309385322
Earnings Before Taxes-108.0%-68.008521,9471,6143,4421,7482,3921,5311,6752,1312,1555581,8571,8772,2062,0302,0201,9832,2772,5642,314
EBT Margin-47.2%0.15*0.28*0.33*0.35*0.35*0.28*0.29*0.28*0.25*0.26*-----------
Net Income-114.7%-1137671,7301,3792,8411,6162,1431,3171,4761,8991,8844641,6461,6152,0211,8031,8251,7031,9682,1791,992
Net Income Margin-46.5%0.13*0.24*0.28*0.30*0.30*0.25*0.26*0.25*0.22*0.23*-----------
Free Cashflow58.8%4592892,5123,8387202,3092,8181,6841,9742,521-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-4.3%92,98097,15490,53490,26988,72065,12163,70059,29459,19661,16564,99359,77362,53962,94864,63765,01161,66959,70759,53559,37363,997
  Current Assets-7.6%28,02930,33248,47747,38044,70322,18624,06219,32218,52019,38524,38019,09921,29921,14422,66122,89518,81318,44031,05130,74635,151
    Cash Equivalents-11.3%9,70810,94434,70034,24831,5607,6299,5025,2036,5287,98911,9696,6306,1126,2669,0879,1457,6876,03711,4155,5257,358
  Inventory-8.3%8,7249,5185,0264,9785,0114,9304,7574,5544,4114,0864,1524,1154,0173,8933,9423,8403,6823,5843,2433,1763,016
  Net PPE1.0%6,0025,9415,5635,5325,4605,4275,1885,1585,1425,1844,9824,9064,8554,8894,8164,8434,8794,9284,9014,8824,892
  Goodwill-0.3%18,57018,6293,06215,53115,53115,52914,84514,86514,89714,89014,66514,67614,67314,68914,67414,67814,68314,70314,70526.0014,692
  Current Liabilities7.2%19,71418,39216,95417,09714,21515,68714,33112,61812,88612,18414,84214,58512,86911,6539,95310,52311,82712,83510,73710,62212,706
  Long Term Debt-4.9%60,06163,17059,04059,37760,76137,35437,16135,70536,01033,22233,29128,45831,12932,89534,19634,13330,00826,95027,74227,79829,319
    LT Debt, Current174.4%3,9591,4431,4282,1678341,5911,54381784487.004,2884,3241,55691.0091.0091.001,8402,9532,0492,8163,705
    LT Debt, Non Current-4.9%60,06163,17059,04059,37760,76137,35437,16135,70536,01033,22233,29128,45831,12932,89534,19634,13330,00826,95027,74227,79829,319
Shareholder's Equity-19.4%5,0226,2327,6566,7815,3483,6613,6532,4199166,7008,2178,2479,3349,40910,95910,6599,4859,67310,92710,79410,832
  Retained Earnings-5.0%-27,870-26,549-24,971-25,540-26,919-28,622-28,066-28,252-29,568-24,600-22,964-22,762-21,639-21,408-19,851-20,168-21,378-21,330-20,136-20,054-19,895
Shares Outstanding0.2%536535535535534534535541548570572575---------
Float----118,556---129,940---137,531---138,057---110,809-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations28.1%6895382,7604,1091,0642,6492,9781,9302,1642,8082,4181,9312,1042,1533,3682,8422,1342,5143,3771,4141,845
  Share Based Compensation-103---47.00----------------
Cashflow From Investing99.2%-217-27,089-262-2111,358-3,473-267-2,193-111-23073.001,209-319-1,384-1,628-2,159-230-5,9635,3722,7453,555
Cashflow From Financing-162.0%-1,7082,754-2,005-1,21021,509-1,0491,588-1,062-3,514-6,5582,848-2,622-1,939-3,590-1,798775-254-1,929-2,859-5,992-4,987
  Dividend Payments6.0%1,2081,1401,1401,1391,1371,0401,0381,0381,0809909991,0081,016932936942945860868880901
  Buy Backs------900-50.006,3101,4461,0691,5928651,2087525919331,1231,1702,3493,031
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AMGN Income Statement

2024-03-31
Condensed Consolidated Statements of (Loss) Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 7,447$ 6,105
Operating expenses:  
Cost of sales3,2001,720
Research and development1,3431,058
Selling, general and administrative1,8081,258
Other105148
Total operating expenses6,4564,184
Operating income9911,921
Other income (expense):  
Interest expense, net(824)(543)
Other (expense) income, net(235)2,064
(Loss) income before income taxes(68)3,442
Provision for income taxes45601
Net (loss) income$ (113)$ 2,841
(Loss) earnings per share:  
Basic (in usd per share)$ (0.21)$ 5.32
Diluted (in usd per share)$ (0.21)$ 5.28
Shares used in calculation of (loss) earnings per share:  
Basic (in shares)536534
Diluted (in shares)536538
Product sales  
Revenues:  
Total revenues$ 7,118$ 5,846
Other revenues  
Revenues:  
Total revenues$ 329$ 259

AMGN Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 9,708$ 10,944
Trade receivables, net6,7767,268
Inventories8,7249,518
Other current assets2,8212,602
Total current assets28,02930,332
Property, plant and equipment, net6,0025,941
Intangible assets, net31,37232,641
Goodwill18,57018,629
Other noncurrent assets9,0079,611
Total assets92,98097,154
Current liabilities:  
Accounts payable1,6281,590
Accrued liabilities14,12715,359
Current portion of long-term debt3,9591,443
Total current liabilities19,71418,392
Long-term debt60,06163,170
Long-term deferred tax liabilities1,8622,354
Long-term tax liabilities3,9644,680
Other noncurrent liabilities2,3572,326
Contingencies and commitments
Stockholders’ equity:  
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—536.4 shares in 2024 and 535.4 shares in 202333,08233,070
Accumulated deficit(27,870)(26,549)
Accumulated other comprehensive loss(190)(289)
Total stockholders’ equity5,0226,232
Total liabilities and stockholders’ equity$ 92,980$ 97,154
AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
 CEO
 WEBSITEamgen.com
 INDUSTRYPharmaceuticals
 EMPLOYEES25200

Amgen Inc Frequently Asked Questions


What is the ticker symbol for Amgen Inc? What does AMGN stand for in stocks?

AMGN is the stock ticker symbol of Amgen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amgen Inc (AMGN)?

As of Fri Jul 19 2024, market cap of Amgen Inc is 177.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers. The fair value of Amgen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amgen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amgen Inc a good stock to buy?

The fair value guage provides a quick view whether AMGN is over valued or under valued. Whether Amgen Inc is cheap or expensive depends on the assumptions which impact Amgen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMGN.

What is Amgen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, AMGN's PE ratio (Price to Earnings) is 47.23 and Price to Sales (PS) ratio is 6.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amgen Inc's stock?

In the past 10 years, Amgen Inc has provided 0.133 (multiply by 100 for percentage) rate of return.